To determine whether HDAC inhibitors may be worthwhile evaluating in the treatment of adult ALL, we examined the acetylation of histone H4 in patients with newly diagnosed ALL and evaluated the impact of acetylation on complete remission (CR) rate, relapse-free survival (RFS), and overall survival (OS). Here, HDAC9 is linked to acute lymphoblastic leukemia.